Temporary Fillers. Dermatologic Surgery: Step By Step. Sep 2012, Pages: 259–285, 2012

Soft-Tissue Augmentation With Hyaluronic Acid And Calcium Hydroxyl Apatite Fillers. Dermatologic Therapy. Volume 24, Issue 1, January/February 2011, Pages: 71–81

Facial Soft-Tissue Fillers Conference: Assessing The State Of The Science. Journal Of American Academy Of Dermatology. Volume 127, Issue 4, 2011, Pages: 22s-S

Facial Soft-Tissue Fillers Conference: Assessing The State Of The Science. Journal Of American Academy Of Dermatology. Volume 64, Issue 4, 2011, Pages: 66-85

Guidelines For Local Anesthesia In Use Of Injectable Fillers. Injectable Fillers: Principles And Practice. March 2010, Pages: 8–18

Letter: Additional Commentary on “Addition of Lidocaine to Fillers”. Dermatologic Surgery. Volume 36, Issue 11, November 2010, Pages: 1795–1796

Controlled, Randomized Study Of Pain Levels In Subjects Treated With Calcium Hydroxylapatite Premixed With Lidocaine For Correction Of Nasolabial Folds. Dermatologic Surgery. Volume 36, Issue 3, 2010, Pages: 309–315

Multicenter, Randomized Trial Assessing The Effectiveness And Safety Of Calcium Hydroxylapatite For Hand Rejuvenation. Dermatologic Surgery. Volume 36, Issue 1, 2010, Pages: 790–797

Calcium Hydroxylapatite (Radiesse) For Treatment Of Nasolabial Folds: Long-Term Safety And Efficacy Results. Aesthetic Surgery Journal. March 2010, Volume 30 Issue 2, Pages: 235-8

Forehead Recontouring Using Calcium Hydroxylapatite. Dermatologic Surgery. Volume 36, Issue S3, November 2010, Pages: 1910–1913

Calcium Hydroxylapatite (Radiesse): Safety, Techniques And Pain Reduction. Journal Of Drugs In Dermatology. Volume 8, Issue 10, October 2009, Pages: 21-3

Soft Tissue Augmentation: Nonsurgical Approaches To Treatment Of The Mid And Lower Facial Regions. Dermatology Nursing. Volume 20, Issue 3, June 2008, Pages: 211-214, 217-219

An Investigation Of Changes In Physical Properties Of Injectable Calcium Hydroxylapatite In A Carrier Gel When Mixed With Lidocaine And With Lidocaine/ Epinephrine. Dermatologic Surgery, Volume 34, Issue 1, 2008, Pages: 16-24

Hand Augmentation With Radiesse® (Calcium Hydroxylapatite). Dermatologic Therapy. Volume 20, Issue 6, November 2007, Pages: 385–387

Five-Year Safety And Efficacy Of A Novel Polymethylmethacrylate Aesthetic Soft Tissue Filler For The Correction Of Nasolabial Folds. Dermatologic Surgery. Volume 32, Issue 2, December 2007, Pages: 222-230

A Randomized, Bilateral, Prospective Comparison Of Calcium Hydroxylapatite Microspheres Versus Human-Based Collagen For The Correction Of Nasolabial Folds. Dermatologic Surgery, Volume 33, Issue 2, 2007, Pages:112–121

Artefill: A Long-Lasting Injectable Wrinkle Filler Material–Summary Of The U.S. Food And Drug Administration Trials And A Progress Report On 4- To 5-Year Outcomes. Plastic And Reconstructive Surgery. September 2006, Volume 118, Issue 3, Pages: 64-76

Soft Tissue Augmentation With Artecoll: 10-Year History, Indications, Techniques, And Complications Dermatologic Surgery. Volume 29, Issue 6, June 2003, Pages: 573–587

Nucleotide Dimers As Anti Human Immunodeficiency Virus Agents. Nucleotide Analogues As Antiviral Agents. August 1989, Pages: 156-169

Cosmetic Dermatology Procedure Manual. Leonard AL and Hanke CW (ed). Physicians’ Continuing Education Corp. 2007; 67-72.

Prepackaged injectable soft-tissue rejuvenation of the hand and other nonfacial areas. In: Alam M and Pongprutthipan M, eds. Body Rejuvenation (Part 7). New York: Springer. 2010;30:221-225

Anti-HIV screening technology. Heterosexual transmission of AIDS. Alexander N (ed). Wiley-Liss 1989; 311-327.

Discovery, Synthesis, And Bioactivity Of Bis(Heteroaryl)Piperazines. 1. A Novel Class Of Non-Nucleoside Hiv-1 Reverse Transcriptase Inhibitors. Journal Of Medical Chemistry. 1994, Volume 37, Issue 7, Pages: 999-1014

Bis(Heteroaryl)Piperazine (Bhap) Reverse Transcriptase Inhibitors: Structure-Activity Relationships Of Novel Substituted Indole Analogs And The Identification Of 1-[(5-Methanesulfonamido-1h-Indol-2-Yl)Carbonyl]-4-[3-[(1-Methylethyl)Amino]Pyridinyl] Piperazinemonomethanesulfonate (U-90152s), A Second-Generation Clinical Candidate. Journal Of Medicinal Chemistry. 1993, Volume 36, Issue 10, Pages:1505-1508

Calcium Hydroxylapatite (RADIESSE) for Correction of the Mid- and Lower Face: Consensus Recommendations. Plastic Reconstructive Surgery. November 2007, 120 (6), 55-66.

Vectoring Approach to Facial Recontouring Using Calcium Hydroxylapatite (Radiesse®) and Hyaluronic Acid (Restylane®). Cosmetic Dermatology. 2009, 22(10), 522-28.

Midfacial and Lower Facial Recontouring Using Calcium Hydroxylapatite (Radiesse®). Healthy Aging E-Newsletter, May 2010.

Cheek augmentation and rejuvenation using injectable calcium hydroxylapatite (Radiesse).Cosmetic Dermatology. September 2006, 19(9), 583-588.

Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy. Journal of American Academy of Dermatology. February 1999, 40(2 Pt 2), 315-317.

Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis. 1997, 60, 289-290.

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochemical Pharmacology. March 1996, 51(6), 743-750.

Antivirals in Dermatology. Journal of American Academy of Dermatology. 1995, 32, 1031-1040.

Development of an assay that detects transcriptionally active component Human Immunodeficiency Virus type one particles. Journal of Virology Methods. 1994, 47, 129-140.

U-90152; a potent inhibitor of HIV-1 replication. Antimicrobial Agents in Chemotherapy. 1993, 37, 1127-1131.

BHAP reverse transcriptase inhibitors: Structure activity relationships of novel subs-tituted indole analogues and the indentification of a second generation chemical candidates. Journal of Medical Chemistry. 1993, 36, 1505-1508.

Enzymatic kinetics studies with the non-nucleoside HIV RT inhibitor U-9843. Experience. 1992, 48, 1127-1132.

Novel bisheteroarylpiperazine HIV-1 reverse transcriptase inhibitors which potently inhibit viral replication in vitro. Proceedings of the National Academy Science USA. 1991, 88, 8806-8810.

HIV-induced syncytium formation requires the formation of conjugates between virus infected and uninfected T-cells in vitro. AIDS. 1991, 5, 1425 1432.

Anti-HIV effects of dextran sulfate are strain dependent and antagonistic or synergistic when dextran sulfate is given in combination with dideoxynucleosides. Antimicrobical Agents Chemotherapy. 1990, 34, 19911995.

Cellular pharmacology and anti-HIV activity of 2’,3’ dideoxyguanosine. AIDS Research Human Retroviruses. 6, 1991-1995.

Clinical response to IL-2/LAK therapy of advanced melanoma in an HIV positive patient. Cancer Detection and Prevention. 1989, 7, 835-839.

Uptake of 2’, 3’ dideoxyadenosine in HIV infected and non-infected human cells. AIDS Research Human Retroviruses. 1989, 5, 527-536.

Nucleotide dimers suppress HIV expression in vitro. AIDS Research Human Retroviruses. 1988, 4, 449-455.


Published Abstracts and Presentations

Novel Method that Detects Transcriptionally Active Viral Particles. Annual Meeting of the Laboratory of Tumor Cell Biology. Bethesda, Maryland, 1993.

Novel method to detect transcriptionally active HIV particles. IX International Conference on AIDS, Berlin, Germany, 1993.

Comparative evaluation of spermicidal agents with virucidal activity against HIV. IX International Conference on AIDS, Berlin, Germany, 1993.

HIV V3 Sequence Analysis of the Dental Clade and surrounding Florida Community. Annual Meeting of the Laboratory of Tumor Cell Biology, Bethesda, Maryland, 1992.

Synthesis and anti-HIV activity of 8-methoxy 2’, 3’-dideoxyadenosine-5’-monophosphate (OCH3-dAMP). American Association for Cancer Research, 1992.

Regulation of HIV-induced syncytium formation by inhibitors of conjugate formation. IV NCDDG Meeting, San Diego, CA, 1991.

Mode of action studies with the HIV RT inhibitor U-9843. IV Chemical Congress of N.A., New York, NY, 1991.

HIV-induced syncytium formation requires the formation of conjugates between virus infected and uninfected T-cells in vitro. Gallo Lab of Tumor Cell Biology Meeting, Bethesda, MD, 1991.

Discovery, SAR, and antiviral activity of novel BHAP HIV-1 R inhibitor. ICAAC, Chicago, IL 1991 and IV NCDDG, San Diego, CA, 1991.

Mode of action in vitro studies with the HIV RT inhibitor U-9843. VII International Conference on AIDS, Florence, Italy. 1991.

The search for HIV reverse transcriptase inhibitors. International Conference on AIDS. Florence, Italy, 1991.

The antiviral effect of dextran sulfate (DXS) is HIV-strain dependent. V International Conference on AIDS, Montreal, Canada, 1990.

Studies of anti-HIV activity and metabolism of 2’-3’-dideoxyguanosine (ddG). V International Conference on AIDS, Montreal, Canada , 1989.

Clinical response to IL-2/LAK therapy of advanced melanoma in a HIV positive patient. American and ISPO, Nice, France, 1989.

Cellular pharmacology and anti-HIV activity of 2’-3’ -dideoxyguanosine. American Association for Cancer Research, San Francisco. CA, 1989.

Rapid anti-HIV screening assay. AIDS National Cooperative Drug Discovery and Development Meeting Oakland, CA, 1998.

Anti-HIV activity of necleotide dimers in vitro. IV International Conference on AIDS, Stockholm, Sweden, 1988.

Studies on the metabolism and uptake of dideoxyadenosine in human lymphocytes. IV International Conference on AIDS, Stockhom, Sweden, 1988.

Studies on (ddA) in human cells. American Association for Cancer Research, San Diego, Ca, 1988.